Psychemedics
Logotype for Psychemedics Corporation

Psychemedics (PMD) investor relations material

Psychemedics has been otc

Psychemedics Q4 2024 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Psychemedics Corporation
Q4 2024 earnings summary23 Mar, 2025

Executive summary

  • Psychemedics Corporation specializes in patented hair-based drug testing, serving corporate, school, and government clients in the US and internationally.

  • 2024 revenue declined 11% year-over-year to $19.7 million, mainly due to lower domestic testing volumes.

  • The company completed a reverse/forward stock split and delisted from Nasdaq, now trading on the OTC Pink Market.

  • Management believes current liquidity is sufficient for at least 12 months, but no fixed credit lines remain.

Financial highlights

  • Revenue: $19.7M in 2024, down from $22.1M in 2023 (-11%); US revenue fell 12%, international rose 22%.

  • Net loss: $(1.9)M in 2024, improved from $(4.2)M in 2023.

  • Gross profit: $7.1M in 2024, down 16% year-over-year.

  • Operating loss: $(1.9)M in 2024, improved from $(2.9)M in 2023.

  • Cash at year-end: $1.4M (down from $2.0M); positive operating cash flow of $929K in 2024.

Outlook and guidance

  • Management expects current cash and future operating profits to cover working capital and capital expenditures for at least the next year.

  • No formal revenue or earnings guidance provided; future growth depends on customer acquisition and market conditions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
Psychemedics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Psychemedics Corporation specializes in providing drug testing services through the analysis of hair samples for detecting drugs of abuse. This includes a broad range of substances such as cocaine, marijuana, PCP, amphetamines (including ecstasy and Adderall), opiates (like heroin and oxycodone), synthetic cannabinoids (e.g., K2 and Spice), benzodiazepines (such as Xanax and Valium), as well as nicotine, fentanyl, and alcohol. The company's testing results offer quantitative information that can indicate the approximate amount of drug ingested and historical data to show a pattern of individual drug use over time. Psychemedics' services cater to various sectors including employers for applicant and employee testing, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation is headquartered in Dallas, Texas, and its shares are listed on the Nasdaq.